risk and increased severity of Crohn's disease progression. However, the biological mechanisms responsible of the underlined smoking effects on UC progression remain largely elusive. Several studies have demonstrated the anti-inflammatory action of cholinergic agonists, such as the main tobacco alkaloid nicotine. The contrasting results observed in clinical studies addressing the role of nicotine in UC opened new questions on the molecular mechanisms at the base of the intrinsic nicotinic anti-inflammatory activity and the possible involvement of other tobacco alkaloids in the observed reduced ulcerative colitis disease risk, progression and relapse rate in smokers. In the present study we aimed to investigate the potential preventive anti-inflammatory activity of a tobacco alkaloid (Alkaloid #1), structurally similar to nicotine, in a murine model of intestinal inflammation. Methods: UC-like symptoms were induced in C57BL/6 male mice (n = 14) by 3.5% DSS administration for 7 days. Mice were then treated with nicotine and Alkaloid #1 at 2 different concentrations in drinking water for a total of 21 days (14 days pre-DSS + 7 days during DSS). During the treatment animals were evaluated for progression and severity of UC symptoms. Results: Daily observations (body weight, intestinal bleeding, hematochezia, etc.) and cytokine analysis revealed a protective alkaloidrelated effect. Although no differences observed on the histological analysis of colons, alkaloid-treated mice showed a reduced body weight loss, intestinal bleeding and hematochezia. Further molecular analysis are ongoing to investigate the molecular mechanisms implicated in the disease progression and amelioration.
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The efficacy of tonsil-derived mesenchymal stem cells conditioned medium in chronic colitis model Background: Tonsil-derived mesenchymal stem cells (TMSCs) obtained from tonsillectomy have many advantages such as a short doubling time, high differentiation capacity, and immune modulatory activity. In previous studies, intraperitoneal administration of TMSC in DSS-induced acute and chronic colitis animal models have shown results of improvement in disease activity index and down regulation of histological grading and pro-inflammatory cytokine expression levels. However, the TMSCs were not observed to migrate to the inflamed intestine in vivo. These results are presumed to be due to the paracrine effect of TMSCs. In this study, we tried to verify the therapeutic effect of TMSCs conditioned medium (TMSCs-CM) in the mouse model of DSS-induced chronic colitis. Methods: In vitro, immunosuppressive effects of TMSCs-CM were confirmed by splenocyte immunosuppression assay. C57BL/6 mouse splenocytes were stimulated with mitogen such as LPS or PMA/Ionomycine, and then cultured in TMSCs-CM or co-cultured with TMSC. After 24 h, proliferation of splenocytes were measured using the cck-8 kit. In vivo, eight-week-old C57BL/6 mice were randomly assigned into four groups: normal, colitis, TMSC, and TMSC-CM groups. Chronic Colitis was induced by oral administration of 1.5% dextran sulfate sodium (DSS) for 5 days followed by 5 days of drinking water continuously for three cycles. TMSC (1x106/500 μl) and TMSC-CM (500 μl) were administered via intraperitoneal injection four times and 12 times. The severity of the colitis was assessed by measuring the disease activity index (DAI), colon length, histologic grading, and cytokine levels. Results: The splenocyte stimulated by LPS showed decreased proliferation when co-cultured with TMSC (3.18 ± 0.07 vs. 2.03 ± 0.12, mean ± standard error mean, control group vs. p = 0.0008, ANOVA), and cultured in TMSC-CM (3.18 ± 0.07 vs. 1.81 ± 0.06, p < 0.0001). Proliferation was significantly reduced by the number of TMSC (p = 0.0055) and TMSC-CM concentration (p = 0.0028). Background: Ustekinumab (UST), targeting the IL-12/23 shared p40 subunit, was recently approved by FDA and EMA for treatment of moderate-to-severe Crohn's disease (CD). The aim of this study was to identify potential predictive immunological biomarkers for response, which may guide treatment strategies with ustekinumab. Methods: Serum samples of 36 CD patients (73% female, median disease duration 15.9 years), all refractory to anti-TNF therapy and vedolizumab and with baseline endoscopic active disease, were prospectively collected prior to UST initiation. Patients received UST 6 mg/kg IV at induction, with subcutaneous UST 90 mg q8w thereafter. Endoscopic response was assessed at week 24, and defined as ≥ 50% SES-CD decrease. Proteomic analysis (OLINK) was performed on baseline serum samples. Additionally, inflamed ileal (n = 10) and colonic (n = 17) biopsies, prior to UST therapy, were collected. Mucosal total RNA was isolated, and next-generation sequencing performed. Differentially gene expression was evaluated by DESeq R package. Results: Patients with (n = 7) and without (n = 29) endoscopic response at week 24 had a similar baseline inflammatory burden, reflected by similar median faecal calprotectin (1800 vs. 1721 µg/g, p = 0.22), C-reactive protein (20.3 vs. 9 .4 mg/l, p = 0.36) and IL-6 (p = 0.37, fold change (FC)=1.06) before start of UST. Baseline endoscopic activity was much higher in patients responding to UST, compared with nonresponders (median SES-CD 21 vs. 13, p < 0.001). Several proteins significantly correlated with baseline SES-CD, but only one protein, CD40 (r = 0.87, p = 0.05), also significantly differed between responders and non-responders before UST initiation (p = 0.029 with corresponding FC 1.46). At baseline, CCL11 also varied between responders and nonresponders (p = 0.06, FC 1.45), but did not correlate with baseline SES-CD (p = 0.97). ROC-statistics showed a significant area under the curve (81.5%, p = 0.011) for prediction of response based on the combination of both. On mucosal level, a non-significant increase in both CD40 and CD40L could be observed in colonic biopsies of responders at baseline (FC 1.6 and 1.5, respectively). Ileal biopsies also expressed increased CD40L in responders (FC 2.0). Conclusions: Two potential predictive biomarkers for response to UST were identified, which need validation in larger and independent cohorts. Because it has been shown that CD40/CD40L-triggering of dendritic cells induces expression of high levels of IL-23 and not IL-12, low CD40 levels in non-responders suggest another mechanism, apart from the IL-12/23 pathway, driving inflammation in these patients. These findings may aid in individualised selection of biological agents in Crohn's disease, and provide mechanisms of primary (non-)response to UST.
